Abstract:BackgroundDuchenne Muscular Dystrophy (DMD) is the most common muscle disease in children, and there are no effective therapies for DMD or Becker Muscular Dystrophy (BMD). Currently, targeted gene therapy treatments have emerged. As a result, genetic diagnosis is the basis of treatment. In addition, genetic and prenatal diagnosis significantly reduces their incidence rates. This study combines the application of multiplex ligation-dependent probe amplification technology (MLPA) and "next-generation" sequencing technology (NGS) as the most economical and efficient method of diagnosis. Therefore, in the diagnosis of DMD/BMD, patients' MLPA data are first used to detect DMD gene deletions or duplications, and NGS and Sanger sequencing are then applied to exclude MLPA-negative samples. Meanwhile, polymerase chain reaction (PCR) is used to detect single exon deletions to exclude false-positives in MLPA caused by point mutations.MethodsIn this study, we recruited 1051 proband families of DMD from 2016 to 2018 and had access to information that could identify individual participants during or after data collection. Patients who were diagnosed with DMD were first tested by MLPA. MLPA results with single exon deletions were validated with PCR amplification and Sanger sequencing. The negative results of MLPA were further analysed with NGS and validated by Sanger sequencing. For novel missense mutations, phenotype-genotype correlations were analysed using PolyPhen2 and mutation taster. All methods were performed in accordance with the relevant guidelines and regulations.ResultsDMD mutations were identified in 1029 families (97.91%, 1029/1051). Large deletions, duplications, and small mutations accounted for 70.41% (740/1051), 8.28% (87/1051), and 19.12% (201/1051) of all cases, respectively. There were 205 small mutation types, 53 of which were novel. The rate of de novo mutations was 39.45% (187/474) and was higher in large duplications (49.53%, 157/317). Among 68 asymptomatic patients (< 3 years old) with unexplained persistent hyperCKaemia upon conventional physical examination, 63 were diagnosed as DMD/BMD according to genetic diagnosis.ConclusionOur results expand the spectrum of DMD mutations, which could contribute to the treatment of DMD/BMD and provide an effective diagnosis method. Thus, the combination of MLPA, NGS and Sanger sequencing is of great significance for family analysis, gene diagnosis and gene therapy.

Exonization of a Deep Intronic Long Interspersed Nuclear Element in Becker Muscular Dystrophy

Identification of LAMA2 Compound Heterozygous Variants: a Case Report

Cryptic Exon Activation Caused by a Novel Deep-Intronic Splice-Altering Variant in Becker Muscular Dystrophy.

A Novel Deep Intronic Variant Introduce Dystrophin Pseudoexon in Becker Muscular Dystrophy: A Case Report

Comprehensive Genetic Diagnosis of Patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) and Pathogenicity Analysis of Splice Site Variants in the DMD Gene

Genetic Identification of Pathogenic Variations of the DMD Gene: a Retrospective Study from 10,481 Neonatal Patients Based on Next-Generation Sequencing Data

Long‐read Whole‐genome Sequencing for the Genetic Diagnosis of Dystrophinopathies

Novel Partial Exon 51 Deletion in the Duchenne Muscular Dystrophy Gene Identified via Whole Exome Sequencing and Long-Read Whole-Genome Sequencing

Two Novel Deep Intronic Variants Cause Duchenne Muscular Dystrophy by Splice-Altering Mechanism

Long-Read Sequencing Revealed Extragenic and Intragenic Duplications of Exons 56–61 in DMD in an Asymptomatic Male and a DMD Patient

A new pseudoexon activation due to ultrarare branch point formation in Duchenne muscular dystrophy

Targeted Next-Generation Sequencing As a Comprehensive Test for Patients with and Female Carriers of DMD/BMD: a Multi-Population Diagnostic Study

First Identification of Rare Exonic and Deep Intronic Splice-Altering Variants in Patients With Beta-Sarcoglycanopathy

Functional Analysis of Variants in DMD Exon/intron 10 Predicted to Affect Splicing

Identifying inversions with breakpoints in the Dystrophin gene through long-read sequencing: report of two cases

Clinical, Muscle Imaging, and Genetic Characteristics of Dystrophinopathies with Deep-Intronic DMD Variants.

Comprehensive analysis of genomic complexity in the 5' end coding region of the DMD gene in patients of exons 1–2 duplications based on long-read sequencing

Novel Noncontiguous Duplications Identified with a Comprehensive Mutation Analysis in the DMD Gene by DMD Gene-Targeted Sequencing.

RNA Sequencing Facilitates the Identification of Genetic Causes of Duchenne Muscular Dystrophy and Proposes a Stepwise DMD Diagnostic Procedure

Genetic analysis of 1051 Chinese families with Duchenne/Becker Muscular Dystrophy

DMD mutations in pediatric patients with phenotypes of Duchenne/Becker muscular dystrophy